



## **Press Release**

### **ShigaMediX enters into R&D agreement with GSK Biologicals**

Paris, November 20, 2007. ShigaMediX announced today the signature of an agreement with GlaxoSmithKline Biologicals for the development of immunotherapeutic approaches based on ShigaMediX's new delivery approach aimed at optimizing the interactions of selected antigens with the immune system.

“We are indeed very pleased to have this collaboration with GSK Biologicals, one of the global vaccine leaders, said Jean-Marie Zacharie, CEO of ShigaMediX. This agreement is a clear indication that ShigaMediX 's innovative delivery approach constitutes a promising technology to develop innovative therapeutic vaccines and it gives our company large opportunities of business development.”

Under the financial terms of the agreement, ShigaMediX will receive an upfront payment followed by milestones. R&D costs will be co-funded by both companies.

### **About ShigaMediX**

ShigaMediX is the first company issued from the research valorization policy of The Curie Institute in Paris. The company was founded in 2005, and is granted a worldwide exclusive license on a patents portfolio owned by Curie Institute, INSERM, CNRS and Paris 6 University. As a biopharmaceutical company, ShigaMediX focuses on the development of new effective and safe vaccines for the treatment of cancers and infectious diseases. The company develops internal programs, and enters in co-development programs with pharmaceutical partners.

#### **Contact :**

Jean-Marie ZACHARIE, CEO  
Incubateur Paris Biotech Santé  
24, rue du Faubourg Saint-Jacques  
75014 Paris  
France  
Tél. +33 (0) 53105335  
Fax. +33 (0) 53105311  
Mail : [jmzacharie@shigamedix.com](mailto:jmzacharie@shigamedix.com)